Journal Mobile Options
Table of Contents
Vol. 66, No. 6, 2011
Issue release date: December 2011
Eur Neurol 2011;66:343–349
(DOI:10.1159/000332585)

White Matter Hyperintensity as a Factor Associated with Delayed Mood Disorders in Patients with Acute Ischemic Stroke

Kim J.-T. · Park M.-S. · Yoon G.-J. · Jung H.-J. · Choi K.-H. · Nam T.-S. · Lee S.-H. · Choi S.-M. · Kim B.-C. · Kim M.-K. · Cho K.-H.
aDepartment of Neurology, Cerebrovascular Center, Chonnam National University Hospital, Gwangju, and bDepartment of Neurology, Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Mood disorder is a frequent complication of stroke. Comorbid depressive and anxiety disorders are very common, indicating that it is advisable to assess both disorders at the same time. The aim of the present study was to examine the prevalence of post-stroke depression (PSD) and poststroke anxiety (PSA) at baseline and to evaluate factors related to delayed PSD and PSA at 3 months after stroke onset. Methods: This was a prospectively registered and retrospectively analyzed study of patients with acute ischemic stroke between January 2009 and March 2010. Patients included in this study were interviewed in order to evaluate their Hospital Anxiety and Depression Scale (HADS) scores. In this study, each depression and anxiety score was dichotomized into ‘nondepressive and nonanxious’ (HADS-D and HADS-A ≤7) and ‘depressive and anxious’ (HADS-D and HADS-A >7). Multiple logistic regression analysis was used to evaluate the independent factors of depressive and anxious symptoms 3 months after stroke onset. Results: Of the 133 patients, 47.4% were ‘depressive’ and 56.4% were ‘anxious’ at baseline. The depressive and anxious groups had a significantly higher frequency of severe white matter hyperintensity (WMH) than the nondepressive and nonanxious groups (p < 0.05). The independent factors of PSD and PSA at 3 months were deep white matter hyperintensities (DWMH) and modified Rankin scale 0 to 1 at 3 months. Conclusion: In conclusions, the results of our study demonstrated that delayed depression and anxiety after ischemic stroke were related to the severity of DWMH and unfavorable outcomes at 3 months, regardless of anti-anxiety treatment. Our results suggested that WMH might be associated with pathomechanism of delayed depression and anxiety.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Hackett ML, Yapa C, Parag V, Anderson CS: Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330–1340.
  2. Hadidi N, Treat-Jacobson DJ, Lindquist R: Poststroke depression and functional outcome: a critical review of literature. Heart Lung 2009;38:151–162.
  3. Chemerinski E, Robinson RG, Arndt S, Kosier JT: The effect of remission of poststroke depression on activities of daily living in a double-blind randomized treatment study. J Nerv Ment Dis 2001;189:421–425.
  4. Shimoda K, Robinson RG: The relationship between poststroke depression and lesion location in long-term follow-up. Biol Psychiatry 1999;45:187–192.
  5. Astrom M, Adolfsson R, Asplund K: Major depression in stroke patients: a 3-year longitudinal study. Stroke 1993;24:976–982.
  6. Robinson RG, Starr LB, Kubos KL, Price TR: A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke 1983;14:736–741.
  7. Carson AJ, MacHale S, Allen K, et al.: Depression after stroke and lesion location: a systematic review. Lancet 2000;356:122–126.
  8. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 2000;57:1071–1076.
  9. Lamers F, van Oppen P, Comijs HC, et al: Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands study of depression and anxiety (NESDA). J Clin Psychiatry 2011.
  10. Mancini M, Perna G, Rossi A, Petralia A: Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother 2010;11:1167–1181.
  11. Castillo CS, Starkstein SE, Fedoroff JP, Price TR, Robinson RG: Generalized anxiety disorder after stroke. J Nerv Ment Dis 1993;181:100–106.
  12. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.
  13. De Wit L, Putman K, Baert I, et al.: Anxiety and depression in the first six months after stroke: a longitudinal multicentre study. Disabil Rehabil 2008;30:1858–1866.
  14. Blier P, Bergeron R, de Montigny C: Selective activation of postsynaptic 5-ht1a receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16:333–338.
  15. Chatterjee K, Fall S, Barer D: Mood after stroke: a case control study of biochemical, neuro-imaging and socio-economic risk factors for major depression in stroke survivors. BMC Neurol 2010;10:125.
  16. Tang WK, Chen YK, Lu JY, et al: White matter hyperintensities in post-stroke depression: a case control study. J Neurol Neurosurg Psychiatry 2010;81:1312–1315.
  17. Taylor WD, Steffens DC, MacFall JR, et al: White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 2003;60:1090–1096.
  18. Black S, Gao F, Bilbao J: Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke 2009;40:S48–S52.
  19. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M: ‘Vascular depression’ hypothesis. Arch Gen Psychiatry 1997;54:915–922.
  20. Herrmann M, Bartels C, Schumacher M, Wallesch CW: Poststroke depression. Is there a pathoanatomic correlate for depression in the postacute stage of stroke? Stroke 1995;26:850–856.
  21. Vataja R, Pohjasvaara T, Leppavuori A, et al: Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry 2001;58:925–931.
  22. Bhogal SK, Teasell R, Foley N, Speechley M: Lesion location and poststroke depression: systematic review of the methodological limitations in the literature. Stroke 2004;35:794–802.
  23. Teodorczuk A, Firbank MJ, Pantoni L, et al: Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med 2010;40:603–610.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50